In 1968 Walshe described arthralgia associated with positive LE cells (in two of his patients with Wilson's disease) which subsided on reducing the penicillamine dosage (Walshe 1968 ). Since then there have been several reports of arthritis, arthralgia or systemic connective tissue disorder occurring in the course of penicillamine therapy. For example, arthralgia, fever, serositis, LE cells and positive antinuclear factor (ANF) have been described in patients given penicillamine for Wilson's disease or cystinuria (Golding & Walshe 1976 , Harpey et al. 1971 , Maini 1975 , Moran 1975 . Moran (1975) described 2 patients suffering from rheumatoid arthritis who developed lupuslike reactions: a woman treated with penicillamine for five months who had an SLE-like rash which disappeared three weeks after stopping the drug; and a 13-year-old boy with Still's disease who, after taking penicillamine for 15 months, developed pleurisy, positive ANF and raised DNA-binding. At the same meeting Maini (1975) stated that features of LE had been noted in 2 of 100 penicillamine-treated patients: one had antibody to double-stranded DNA, which is said to be unusual in drug-induced lupus; the other had ANF positive at 1/1000, with 100% DNA binding.
We have reviewed 30 patients with Wilson's disease with regard to musculoskeletal abnormalities. This series contained 5 patients who at some time had developed an arthropathy thought to be related to penicillamine therapy. Episodes of acute arthritis or rheumatism are a very uncommon feature of untreated Wilson's disease, in which various forms of chronic joint change (mainly degenerative in nature) are now recognized (Golding & Walshe 1977) . In this series the rheumatic illness presumed to be penicillaminenduced fell into three groups: an acute rheumatism-like reaction (Type I) in one patient, an arthritis resembling (sero-negative) rheumatoid arthritis (Type II) in 2 patients, and an acute arthritis with serological features of SLE (Type III) in 2 patients. The patient with Type I reaction had a fleeting polyarthritis with pyrexia and sore throat, initially thought to be rheumatic fever. In the Type II patients the pattern of joint involvement, tendon lesions and subsequent course of the arthritis was identical to that of rheumatoid disease. The Type III patients had acute arthropathy and serological features of SLE similar to drug-induced lupus reactions and previously recorded cases of penicillamine arthropathy.
Outside the present series, Walshe has seen 2 other Wilson's patients who had no rheumatic symptoms but in whom positive ANFs (titres around 1:80) were recorded. Another patient (male) developed progressive weight loss, a high ESR, strongly positive tests for rheumatoid factor and ANF, and cutaneous vasculitis where IgG or IgM deposits were identified in the involved skin vessels. Table 1 summarizes the clinical, radiological and immunological features of the 5 patients in the present series thought to have had penicillamine-induced arthropathy. All were females. Penicillamine had been taken for between two and seven years before the rheumatic illness occurred. Two patients have had only one attack of arthritis to date, the others continuing to suffer from intermittent joint troubles. In only one patient (CR) was the arthropathy sufficiently severe and prolonged to necessitate stopping penicillamine: this patient has been taking trien 2HCI and systemic steroids ever since. Her joint symptoms have been less since stopping penicillamine but have never remitted. A single test dose of the drug induced an attack of acute joint pain for 24 hours. In the remaining patients, the joint symptoms have been adequately managed by reducing the penicillamine dosage, prescribing anti-inflammatory drugs other than steroids, and offering other appropriate treatment such as local steroid injections and physiotherapy.
Penicillamine-induced arthropathy and LElike connective-tissue disorders are thought to be reactions of the delayed hypersensitivity type where penicillamine, acting as a hapten, combines with epidermal protein containing cysteine to produce an antibody which sensitizes lymphocytes causing cell death, release of cellular antigens and consequent secondary lymphocyte sensitization. Antibodies to penicillamine, which have been demonstrated occasionally in these patients, were shown to be present in one patient in the present series (LE).
Penicillamine is life-saving in Wilson's disease and the aim must be to continue this drug in all but the most severe and unremitting cases of arthropathy. When penicillamine-treated rheumatoid patients are considered, a rather different attitude can be adopted. It must be remembered that, firstly, transient increase in joint pain is not uncommon on starting the drug. Then, after some months or years of treatment, it is conceivable that an exacerbation of rheumatoid activity might 'break through' the current penicillamine dosage. Increase in dosage may then be indicated, but first serological assessment is advisable: the presence of large numbers of LE cells, or rise in titre of ANF, probably indicates a lupus reaction, when it may be advisable to discontinue (rather than increase) the drug.
There is conflict of opinion about the significance of raised DNA-binding in such instances. Positive ANF with negative DNA-binding, such as occurred in both our patients with Type III reactions, is the usually accepted pattern in druginduced lupus, but there have been reports of raised DNA-binding with positive ANF in penicillamine-treated rheumatoid patients (Moran 1975 , Maini 1975 . Should antibodies to doublestranded DNA be found this may represent additional evidence of a more definite (and perhaps irreversible) connective tissue reaction than that which occurs in recognized forms of drug-induced lupus. 
DISCUSSION
Dr H Berry (London): Was there any histological evidence that the patient with a DNA binding of 30 % did not have SLE, and that the patient with synovial involvement and ruptured tendon sheaths did not have rheumatoid arthritis? May we be dealing with rheumatoid arthritis and SLE rather than a disease entity on its own induced by penicillamine ? Dr Golding: We had no histological evidence, and I agree that this is a possibility. It could not be proved that those with rheumatoid-like features did not have rheumatoid arthritis and perhaps they did, but perhaps also the penicillamine either induced or worsened their rheumatoid disease.
Dr Sumner (Leeds): On a slightly frivolous note, six years ago I saw a girl of 20 with a peculiar dystonic disease. It was not Wilson's disease but we gave her penicillamine. Within 24 hours her behaviour became very odd. I told her sharply to get betterwhich she did. The whole illness was clearly hysterical and now she is well, but I cannot wean her off her 500 mg of penicillamine daily: it is a drug of addiction! What can I do with her? I monitor her liver and other parameters, but she just gets worse again if I stop the drug!
